Mallinckrodt to Present Data on Terlipressin
Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of four posters on hepatorenal syndrome (HRS) at The Liver Meeting in Washington, D.C.
About Hepatorenal Syndrome (HRS)
Hepatorenal syndrome (HRS) is a life-threatening condition that occurs in people with advanced liver disease.
- HRS is classified into two types:
- HRS-acute kidney injury (AKI), a rapidly progressive type leading to renal failure
- HRS-chronic kidney disease (CKD), a more chronic type progressing slowly over weeks to months
- HRS affects over 60,000 Americans annually, approximately 0.01% of the U.S. population
- Rates of HRS hospitalizations are increasing
Author's summary: Mallinckrodt presents data on Terlipressin at AASLD meeting.
More News
- Pacific Defence Ministers escalate militarisation across the region
- England warned of ongoing drought risk into 2026 - Farmers Weekly
- Illinois lawmakers hike toll roads and sales taxes to fund Chicago-area transit
- United States: Organising to resist mass immigrant raids
- Educators and students speak out against pro-business, militarist assault on Australian university jobs